This content is sponsored by Novo Nordisk. The author attended the conference with assistance from Novo Nordisk.

_{Conflict of interest disclaimers: Dr Jessica Lai has received educational grants from Novo Nordisk. Dr Kiernan Hughes has received advisory board fees, educational travel grants and speak fees from MSD, Sanofi, AstraZeneca, Eli Lilly and Novo Nordisk.}

Yet more evidence has emerged that two classes of diabetes medications improve cardiovascular disease outcomes in people with type 2 diabetes.

At the recent American Diabetes Conference, SGLT-2 inhibitors and GLP-1 receptor agonists continued to show efficacy for glycaemic control and weight loss, as well as favourable changes in CV risk factors.